BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. [PMID: 26213556 DOI: 10.7573/dic.212283] [Cited by in Crossref: 197] [Cited by in F6Publishing: 212] [Article Influence: 24.6] [Reference Citation Analysis]
Number Citing Articles
1 Grigson PS, Hobkirk AL. Addiction III: From mouse to man. Brain Res Bull 2023;193:22-6. [PMID: 36464128 DOI: 10.1016/j.brainresbull.2022.12.001] [Reference Citation Analysis]
2 Xie X, Valiente PA, Kim PM. HelixGAN a deep-learning methodology for conditional de novo design of α-helix structures. Bioinformatics 2023;39. [PMID: 36651657 DOI: 10.1093/bioinformatics/btad036] [Reference Citation Analysis]
3 Jujić A, Godina C, Belting M, Melander O, Juul Holst J, Ahlqvist E, Gomez MF, Nilsson PM, Jernström H, Magnusson M. Endogenous incretin levels and risk of first incident cancer: a prospective cohort study. Sci Rep 2023;13:382. [PMID: 36611045 DOI: 10.1038/s41598-023-27509-3] [Reference Citation Analysis]
4 Chirila A, Nguyen ME, Tinmouth J, Halperin IJ. Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice. Journal of the Canadian Association of Gastroenterology 2022. [DOI: 10.1093/jcag/gwac035] [Reference Citation Analysis]
5 Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation 2022;146:1882-94. [PMID: 36508493 DOI: 10.1161/CIRCULATIONAHA.122.059595] [Reference Citation Analysis]
6 Jakhar K, Vaishnavi S, Kaur P, Singh P, Munshi A. Pharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profile. European Journal of Pharmacology 2022;936:175356. [DOI: 10.1016/j.ejphar.2022.175356] [Reference Citation Analysis]
7 Timmermans M, Topal B, Sanches EE, DE Jongh FW, Cagiltay E, Celik A, Ribeiro R, Parmar C, Ugale S, Proczko M, Stepaniak PS, Buise MP, Severin R, Pouwels S. The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery. Minerva Endocrinol (Torino) 2022;47:449-59. [PMID: 33759444 DOI: 10.23736/S2724-6507.21.03296-X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Franch-nadal J, Granado-casas M, Mata-cases M, Ortega E, Vlacho B, Mauricio D. Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world. Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.10.005] [Reference Citation Analysis]
9 Khalifa O, H. Mroue K, Mall R, Ullah E, S. Al-akl N, Arredouani A. Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. Biomedicines 2022;10:2652. [DOI: 10.3390/biomedicines10102652] [Reference Citation Analysis]
10 Amusin DB, Kuchta K, Ewing T, Tucker L, Campbell M, Ujiki MB, Billings LK. Association between hemoglobin A1C response to glucagon-like peptide-1 receptor agonists and hemoglobin A1C and weight outcomes post-bariatric surgery. Obesity Medicine 2022;35:100450. [DOI: 10.1016/j.obmed.2022.100450] [Reference Citation Analysis]
11 Evans B, Stoltzfus B, Acharya N, Nyland JE, Arnold AC, Freet CS, Bunce SC, Grigson PS. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats. Brain Res Bull 2022:S0361-9230(22)00221-0. [PMID: 36038016 DOI: 10.1016/j.brainresbull.2022.08.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Urbanik LA, Acharya NK, Grigson PS. Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats. Brain Res Bull 2022:S0361-9230(22)00222-2. [PMID: 36031011 DOI: 10.1016/j.brainresbull.2022.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bellido V, Abreu Padín C, Catarig A, Clark A, Barreto Pittol S, Delgado E. Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. JCM 2022;11:4938. [DOI: 10.3390/jcm11174938] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Razavi M, Wei Y, Rao X, Zhong J. DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Military Med Res 2022;9. [DOI: 10.1186/s40779-022-00410-2] [Reference Citation Analysis]
15 Ibnat N, Zaman R, Uddin MB, Chowdhury E, Lee CY. Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in rats. World J Diabetes 2022; 13(8): 613-621 [DOI: 10.4239/wjd.v13.i8.613] [Reference Citation Analysis]
16 Zaazouee MS, Hamdallah A, Helmy SK, Hasabo EA, Sayed AK, Gbreel MI, Elmegeed AA, Aladwan H, Elshanbary AA, Abdel-Aziz W, Elshahawy IM, Rabie S, Elkady S, Ali AS, Ragab KM, Nourelden AZ. Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr 2022;16:102511. [PMID: 35623229 DOI: 10.1016/j.dsx.2022.102511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Song R, Qian H, Wang Y, Li Q, Li D, Chen J, Yang J, Zhong J, Yang H, Min X, Xu H, Yang Y, Chen J, Masaki T. Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists. Journal of Diabetes Research 2022;2022:1-8. [DOI: 10.1155/2022/4554996] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Yale JF, Bodholdt U, Catarig AM, Catrina S, Clark A, Ekberg NR, Erhan U, Holmes P, Knudsen ST, Liutkus J, Sathyapalan T, Schultes B, Rudofsky G. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care 2022;10:e002619. [PMID: 35383100 DOI: 10.1136/bmjdrc-2021-002619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chandramoorthy HC, Dera AA, Al-Hakami A, Eid RA, Patel A, Mahmoud Faris N, Devaraj A, Kumar A, Alshahrani MY, Zaman GS, Rajagopalan P. Glucose and oleic acid mediate cellular alterations in GLP-1-induced insulin-positive differentiating UCBMSCs. J Food Biochem 2022;:e14087. [PMID: 35246864 DOI: 10.1111/jfbc.14087] [Reference Citation Analysis]
20 Nikolic D, Patti AM, Giglio RV, Chianetta R, Castellino G, Magán-Fernández A, Citarrella R, Papanas N, Janez A, Stoian AP, Rizvi AA, Rizzo M. Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. Diabetes Ther 2022;13:453-64. [PMID: 35167051 DOI: 10.1007/s13300-022-01217-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Khalifa O, Al-Akl NS, Errafii K, Arredouani A. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Sci Rep 2022;12:2226. [PMID: 35140289 DOI: 10.1038/s41598-022-06143-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
22 Sakran N, Graham Y, Pintar T, Yang W, Kassir R, Willigendael EM, Singhal R, Kooreman ZE, Ramnarain D, Mahawar K, Parmar C, Madhok B, Pouwels S. The many faces of diabetes. Is there a need for re-classification? A narrative review. BMC Endocr Disord 2022;22:9. [PMID: 34991585 DOI: 10.1186/s12902-021-00927-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Atas U, Erin N, Tazegul G, Elpek GO, Yıldırım B. Distribution of transient receptor potential vanilloid-1 channels in gastrointestinal tract of patients with morbid obesity. World J Clin Cases 2022; 10(1): 79-90 [DOI: 10.12998/wjcc.v10.i1.79] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cowart K, Carris NW. Practicable Measurement and Identification of Overbasalization. Clin Diabetes 2022;40:75-7. [PMID: 35221475 DOI: 10.2337/cd21-0096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ferrari F, Scheffel RS, Martins VM, Santos RD, Stein R. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. Am J Cardiovasc Drugs 2021. [PMID: 34958423 DOI: 10.1007/s40256-021-00515-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Watkins JD, Koumanov F, Gonzalez JT. Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review. Adv Nutr 2021;12:2540-52. [PMID: 34192748 DOI: 10.1093/advances/nmab078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Liebman C, Loya S, Lawrence M, Bashoo N, Cho M. Stimulatory responses in α- and β-cells by near-infrared (810 nm) photobiomodulation. J Biophotonics 2021;:e202100257. [PMID: 34837336 DOI: 10.1002/jbio.202100257] [Reference Citation Analysis]
28 Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, Ruotolo G, Haupt A, Newgard CB, Duffin KL. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes. J Clin Endocrinol Metab 2021:dgab722. [PMID: 34608929 DOI: 10.1210/clinem/dgab722] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
29 Nyland JE, Raja-Khan NT, Bettermann K, Haouzi PA, Leslie DL, Kraschnewski JL, Parent LJ, Grigson PS. Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study. Diabetes 2021;70:2903-16. [PMID: 34580086 DOI: 10.2337/db21-0385] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
30 Holmes P, Bell HE, Bozkurt K, Catarig AM, Clark A, Machell A, Sathyapalan T. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. Diabetes Ther 2021;12:2891-905. [PMID: 34562237 DOI: 10.1007/s13300-021-01141-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
31 Tilinca MC, Tiuca RA, Niculas C, Varga A, Tilea I. Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review). Exp Ther Med 2021;22:1167. [PMID: 34504612 DOI: 10.3892/etm.2021.10601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metab Syndr Obes 2021;14:3567-602. [PMID: 34413662 DOI: 10.2147/DMSO.S319895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
33 Sridhar VS, Dubrofsky L, Boulet J, Cherney DZ. Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. J Bras Nefrol 2020;42:467-77. [PMID: 32926067 DOI: 10.1590/2175-8239-JBN-2020-0100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Kuang Z, Cheng X, Yang Z, Guo Y, Huang Y, Su Z. In silico prediction of GLP-1R agonists using machine learning approach. Chem Pap 2021;75:3587-3598. [DOI: 10.1007/s11696-021-01600-3] [Reference Citation Analysis]
35 MacDonald CS, Nielsen SM, Bjørner J, Johansen MY, Christensen R, Vaag A, Lieberman DE, Pedersen BK, Langberg H, Ried-Larsen M, Midtgaard J. One-year intensive lifestyle intervention and improvements in health-related quality of life and mental health in persons with type 2 diabetes: a secondary analysis of the U-TURN randomized controlled trial. BMJ Open Diabetes Res Care 2021;9:e001840. [PMID: 33441418 DOI: 10.1136/bmjdrc-2020-001840] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
36 Tilinca MC, Tiuca RA, Burlacu A, Varga A. A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review. Medicina (Kaunas) 2021;57:669. [PMID: 34209532 DOI: 10.3390/medicina57070669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
37 Sun T, Zhang B, Ru QJ, Chen XM, Lv BD. Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) via restoring the balance of intestinal flora in rats. Pharm Biol 2021;59:723-31. [PMID: 34139927 DOI: 10.1080/13880209.2021.1916542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Borner T, Workinger JL, Tinsley IC, Fortin SM, Stein LM, Chepurny OG, Holz GG, Wierzba AJ, Gryko D, Nexø E, Shaulson ED, Bamezai A, Da Silva VAR, De Jonghe BC, Hayes MR, Doyle RP. Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis. Cell Rep 2020;31:107768. [PMID: 32553160 DOI: 10.1016/j.celrep.2020.107768] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
39 Lu SC, Chen M, Atangan L, Killion EA, Komorowski R, Cheng Y, Netirojjanakul C, Falsey JR, Stolina M, Dwyer D, Hale C, Stanislaus S, Hager T, Thomas VA, Harrold JM, Lloyd DJ, Véniant MM. GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Rep Med 2021;2:100263. [PMID: 34095876 DOI: 10.1016/j.xcrm.2021.100263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
40 Wagner M, Evers A, Bossart M, Konkar A. Glucagon‐Like Peptide‐1 Receptor Activators. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc268] [Reference Citation Analysis]
41 Nejati R, Bijeh N, Rad MM, Hosseini SRA. The impact of different modes of exercise training on GLP-1: a systematic review and meta-analysis research. Int J Diabetes Dev Ctries 2022;42:40-8. [DOI: 10.1007/s13410-021-00950-8] [Reference Citation Analysis]
42 Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:609110. [PMID: 33897616 DOI: 10.3389/fendo.2021.609110] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
43 Akil AA, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J Transl Med 2021;19:137. [PMID: 33794915 DOI: 10.1186/s12967-021-02778-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
44 Icart LP, Souza FG Jr, Lima LMTR. Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists. J Microencapsul 2021;38:249-61. [PMID: 33586588 DOI: 10.1080/02652048.2021.1889059] [Reference Citation Analysis]
45 MacDonald CS, Ried-Larsen M, Soleimani J, Alsawas M, Lieberman DE, Ismail AS, Serafim LP, Yang T, Prokop L, Joyner M, Murad MH, Barwise A. A systematic review of adherence to physical activity interventions in individuals with type 2 diabetes. Diabetes Metab Res Rev 2021;:e3444. [PMID: 33769660 DOI: 10.1002/dmrr.3444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Liu F, Liu Y, Liu M, Wu G, Zhang M, Zhang X, Cui N, Yin H, Chen L. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies. J Diabetes Investig 2021;12:1386-94. [PMID: 33475222 DOI: 10.1111/jdi.13504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Barton JR, Snook AE, Waldman SA. From leptin to lasers: the past and present of mouse models of obesity. Expert Opin Drug Discov 2021;16:777-90. [PMID: 33472452 DOI: 10.1080/17460441.2021.1877654] [Reference Citation Analysis]
48 Mahfooz F, Aylor K, Mathew J Jr, Reichmuth M. Extending our understanding of exenatide: a rare case of angio-oedema. BMJ Case Rep 2021;14. [PMID: 33461993 DOI: 10.1136/bcr-2020-235663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Yaribeygi H, Jamialahmadi T, Moallem SA, Sahebkar A. Boosting GLP-1 by Natural Products. Natural Products and Human Diseases 2021. [DOI: 10.1007/978-3-030-73234-9_36] [Reference Citation Analysis]
50 Chan-Zapata I, Sandoval-Castro C, Segura-Campos MR. Proteins and peptides from vegetable food sources as therapeutic adjuvants for the type 2 diabetes mellitus. Crit Rev Food Sci Nutr 2020;:1-10. [PMID: 33297733 DOI: 10.1080/10408398.2020.1857331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Svensson AM, Toll A, Lebrec J, Miftaraj M, Franzén S, Eliasson B. Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden. Diabetes Obes Metab 2021;23:720-9. [PMID: 33289287 DOI: 10.1111/dom.14276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
52 McGlone ER, Carey I, Veličković V, Chana P, Mahawar K, Batterham RL, Hopkins J, Walton P, Kinsman R, Byrne J, Somers S, Kerrigan D, Menon V, Borg C, Ahmed A, Sgromo B, Cheruvu C, Bano G, Leonard C, Thom H, le Roux CW, Reddy M, Welbourn R, Small P, Khan OA. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses. PLoS Med 2020;17:e1003228. [PMID: 33285553 DOI: 10.1371/journal.pmed.1003228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
53 Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, Rajpathak S, Iglay K. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Patient Prefer Adherence 2020;14:2337-45. [PMID: 33273810 DOI: 10.2147/PPA.S277676] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
54 Pierce-Messick Z, Pratt WE. Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by µ-opioid receptor stimulation of the nucleus accumbens in the rat. Neuroreport 2020;31:1283-8. [PMID: 33165198 DOI: 10.1097/WNR.0000000000001545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
55 Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res 2020;116:916-30. [PMID: 31825468 DOI: 10.1093/cvr/cvz323] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
56 Fitchett DH, Leiter LA, Lin P, Pickering J, Welsh R, Stone J, Gregoire J, McFarlane P, Langer A, Gupta A, Goodman SG. Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open 2020;2:402-15. [PMID: 32995726 DOI: 10.1016/j.cjco.2020.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Di Mauro A, Tuccinardi D, Watanabe M, Del Toro R, Monte L, Giorgino R, Rampa L, Rossini G, Kyanvash S, Soare A, Rosati M, Piccoli A, Napoli N, Fioriti E, Pozzilli P, Khazrai YM, Manfrini S. The Mediterranean diet increases glucagon‐like peptide 1 and oxyntomodulin compared with a vegetarian diet in patients with type 2 diabetes: A randomized controlled cross‐over trial. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgraduate Medicine 2020;132:3-14. [DOI: 10.1080/00325481.2020.1798099] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
59 Kuang J, Zhu J, Liu S, Li Q. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies. Diabetes Ther 2020;11:2329-39. [PMID: 32857293 DOI: 10.1007/s13300-020-00910-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;52:619-36. [PMID: 32638417 DOI: 10.1111/apt.15935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
61 Muzurović E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opinion on Pharmacotherapy 2020;21:2125-35. [DOI: 10.1080/14656566.2020.1795132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Tsao C, Zhang P, Yuan Z, Dong D, Wu K, Niu L, Mcmullen P, Luozhong S, Hung H, Cheng Y, Jiang S. Zwitterionic Polymer Conjugated Glucagon-like Peptide-1 for Prolonged Glycemic Control. Bioconjugate Chem 2020;31:1812-9. [DOI: 10.1021/acs.bioconjchem.0c00286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Staby A, Steensgaard DB, Haselmann KF, Marino JS, Bartholdy C, Videbæk N, Schelde O, Bosch-traberg H, Spang LT, Asgreen DJ. Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs. Pharm Res 2020;37. [DOI: 10.1007/s11095-020-02817-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
64 Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, Tit DM, Corb Aron RA, Zaha DC. Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors. Diagnostics (Basel) 2020;10:E314. [PMID: 32429441 DOI: 10.3390/diagnostics10050314] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 13.7] [Reference Citation Analysis]
65 Dahiya L, Kaur R, Kumar R, Kumar M, Palta K. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus. CDR 2020;16:279-92. [DOI: 10.2174/1573399815666190502114924] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
66 Drzazga A, Okulus M, Rychlicka M, Biegała Ł, Gliszczyńska A, Gendaszewska-Darmach E. Lysophosphatidylcholine Containing Anisic Acid Is Able to Stimulate Insulin Secretion Targeting G Protein Coupled Receptors. Nutrients 2020;12:E1173. [PMID: 32331428 DOI: 10.3390/nu12041173] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
67 Vally M. Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management. SAGP 2020. [DOI: 10.36303/sagp.2020.1.1.0006] [Reference Citation Analysis]
68 William JH, Morales A, Rosas SE. When ESKD complicates the management of diabetes mellitus. Semin Dial 2020;33:209-22. [PMID: 32274852 DOI: 10.1111/sdi.12873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Reed J, Bain S, Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1. F1000Res 2020;9:F1000 Faculty Rev-239. [PMID: 32269764 DOI: 10.12688/f1000research.20602.1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
70 Li YM, Zhang LH, Li XJ, Zhang B, Hou JN, Tong NW. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1. Diabetes Ther 2020;11:1077-90. [PMID: 32219675 DOI: 10.1007/s13300-020-00799-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
71 Jang HN, Jung HS. Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.). Endocrinol Metab (Seoul) 2020;35:194-5. [PMID: 32207281 DOI: 10.3803/EnM.2020.35.1.194] [Reference Citation Analysis]
72 Cowart K. Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin. Clin Diabetes 2020;38:304-10. [PMID: 32699482 DOI: 10.2337/cd19-0061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
73 Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-moerschel L, Schlichthaar H, Klaus B, Ambery PD, Meier JJ, Hirshberg B. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. The Journal of Clinical Endocrinology & Metabolism 2020;105:803-820. [DOI: 10.1210/clinem/dgz047] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
74 Leite KM, Long AM, Ostroff ML, Borges L, Braden G. A Review of the Renoprotective Effects of Novel Antidiabetic Agents. J Pharm Pract 2021;34:141-8. [PMID: 32067559 DOI: 10.1177/0897190020902344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
75 Belete TM. A Recent Achievement In the Discovery and Development of Novel Targets for the Treatment of Type-2 Diabetes Mellitus. J Exp Pharmacol 2020;12:1-15. [PMID: 32021494 DOI: 10.2147/JEP.S226113] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
76 Houda S, Toshihiro U, Yuriko Y, Hiroyuki O, Reie M, Anna S, Masafumi M. Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost. Diabetol Int 2020;11:49-56. [DOI: 10.1007/s13340-019-00404-x] [Reference Citation Analysis]
77 Potential cardiovascular benefits of GLP-1 analogues : evidence and implications for type 2 diabetes management. South African General Practitioner 2020;1:24-29. [DOI: 10.36303/sagp.2020.1.0006] [Reference Citation Analysis]
78 Amaya-cruz D, Peréz-ramírez IF, Pérez-jiménez J, Nava GM, Reynoso-camacho R. Comparison of the bioactive potential of Roselle (Hibiscus sabdariffa L.) calyx and its by-product: Phenolic characterization by UPLC-QTOF MS and their anti-obesity effect in vivo. Food Research International 2019;126:108589. [DOI: 10.1016/j.foodres.2019.108589] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
79 Redij T, Ma J, Li Z, Hua X, Li Z. Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study. J Comput Aided Mol Des 2019;33:973-81. [PMID: 31758355 DOI: 10.1007/s10822-019-00254-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
80 Tavares RS, Escada-Rebelo S, Sousa MI, Silva A, Ramalho-Santos J, Amaral S. Can Antidiabetic Drugs Improve Male Reproductive (Dys)Function Associated with Diabetes? Curr Med Chem 2019;26:4191-222. [PMID: 30381064 DOI: 10.2174/0929867325666181101111404] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
81 Maccora C, Ciuoli C, Goracci A, Benenati N, Formichi C, Pilli T, Verdino V, Mnutr ON, Bufano A, Tirone A, Voglino C, Fagiolini A, Castagna MG. ONE MONTH WEIGHT LOSS PREDICTS THE EFFICACY OF LIRAGLUTIDE IN OBESE PATIENTS: DATA FROM A SINGLE CENTER. Endocr Pract 2020;26:235-40. [PMID: 31682516 DOI: 10.4158/EP-2019-0169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
82 Méndez M, Matter H, Defossa E, Kurz M, Lebreton S, Li Z, Lohmann M, Löhn M, Mors H, Podeschwa M, Rackelmann N, Riedel J, Safar P, Thorpe DS, Schäfer M, Weitz D, Breitschopf K. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). J Med Chem 2020;63:2292-307. [PMID: 31596080 DOI: 10.1021/acs.jmedchem.9b01071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
83 Suzuki R, Brown GA, Christopher JA, Scully CCG, Congreve M. Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. J Med Chem 2020;63:905-27. [PMID: 31577440 DOI: 10.1021/acs.jmedchem.9b00835] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
84 Nuhoho S, Gupta J, Hansen BB, Fletcher-Louis M, Dang-Tan T, Paine A. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. Diabetes Ther 2019;10:2183-99. [PMID: 31599391 DOI: 10.1007/s13300-019-00706-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
85 Gutierrez MDM, Mateo MG, Corbacho N, Vidal F, Domingo P. Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opin Drug Metab Toxicol 2019;15:787-802. [PMID: 31512529 DOI: 10.1080/17425255.2019.1667334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
86 Gao M, Liu D. Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and α1 Antitrypsin. Sci Rep 2019;9:13427. [PMID: 31530849 DOI: 10.1038/s41598-019-49757-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
87 Franch-Nadal J, Mata-Cases M, Ortega E, Real J, Gratacòs M, Vlacho B, Vallés JA, Mauricio D. Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. J Clin Med 2019;8:E1389. [PMID: 31491916 DOI: 10.3390/jcm8091389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
88 Gillenwater BA, Wakefield AN, Triboletti J, Gonzalvo JD, Meredith AH. GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists. AADE in Practice 2019;7:32-41. [DOI: 10.1177/2325160319861453] [Reference Citation Analysis]
89 Kuzulugil D, Papeix G, Luu J, Kerridge RK. Recent advances in diabetes treatments and their perioperative implications. Curr Opin Anaesthesiol 2019;32:398-404. [PMID: 30958402 DOI: 10.1097/ACO.0000000000000735] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
90 Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci 2019;234:116776. [PMID: 31425698 DOI: 10.1016/j.lfs.2019.116776] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
91 Fiory F, Perruolo G, Cimmino I, Cabaro S, Pignalosa FC, Miele C, Beguinot F, Formisano P, Oriente F. The Relevance of Insulin Action in the Dopaminergic System. Front Neurosci. 2019;13:868. [PMID: 31474827 DOI: 10.3389/fnins.2019.00868] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
92 Wang J, Huang J, Li W, Tang S, Sun J, Zhang X, Liu J, Yi B, Liu J, Zhang X, Yang Q, Yang X, Yang S, Yang G, Zhang H. Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. Br J Clin Pharmacol 2019;85:2714-20. [PMID: 31396983 DOI: 10.1111/bcp.14091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
93 Kalra S, Das AK, Sahay RK, Baruah MP, Tiwaskar M, Das S, Chatterjee S, Saboo B, Bantwal G, Bhattacharya S, Priya G, Chawla M, Brar K, Raza SA, Aamir AH, Shrestha D, Somasundaram N, Katulanda P, Afsana F, Selim S, Naseri MW, Latheef A, Sumanatilleke M. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Ther 2019;10:1645-717. [PMID: 31359367 DOI: 10.1007/s13300-019-0669-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
94 Onoviran OF, Li D, Toombs Smith S, Raji MA. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Ther Adv Chronic Dis 2019;10:2040622319862691. [PMID: 31321014 DOI: 10.1177/2040622319862691] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
95 Mata-cases M, Franch-nadal J, Ortega E, Real J, Gratacòs M, Vlacho B, Mauricio D. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area. Current Medical Research and Opinion 2019;35:1735-44. [DOI: 10.1080/03007995.2019.1618806] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
96 Varanko AK, Chilkoti A. Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes. Adv Healthc Mater 2019;8:e1801509. [PMID: 30762299 DOI: 10.1002/adhm.201801509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
97 Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. J Diabetes Investig 2019;10:1518-26. [PMID: 31033218 DOI: 10.1111/jdi.13066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
98 Nolen-doerr E, Stockman M, Rizo I. Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. Curr Obes Rep 2019;8:284-91. [DOI: 10.1007/s13679-019-00350-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
99 Ojha A, Ojha U, Mohammed R, Chandrashekar A, Ojha H. Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus. Clin Pharmacol 2019;11:57-65. [PMID: 31191043 DOI: 10.2147/CPAA.S202614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
100 Zhang Y, Liu S, Fan C, Zeng Y, Li J, Xie C, Xue Y, Guan M. [Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:450-5. [PMID: 31068289 DOI: 10.12122/j.issn.1673-4254.2019.04.11] [Reference Citation Analysis]
101 Routy JP, Isnard S, Mehraj V, Ostrowski M, Chomont N, Ancuta P, Ponte R, Planas D, Dupuy FP, Angel JB; Lilac Study Group. Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. BMJ Open 2019;9:e028444. [PMID: 31005944 DOI: 10.1136/bmjopen-2018-028444] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
102 Howell R, Wright AM, Clements JN. Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date. Diabetes Metab Syndr Obes 2019;12:505-12. [PMID: 31118715 DOI: 10.2147/DMSO.S174568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
103 Dokumacı AH, Yerer Aycan MB. Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1-42 induced toxicity, in vitro. Cytotechnology 2019;71:635-46. [PMID: 30968232 DOI: 10.1007/s10616-019-00312-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Brooks A, Langer J, Tervonen T, Hemmingsen MP, Eguchi K, Bacci ED. Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment. Diabetes Ther 2019;10:735-49. [PMID: 30847838 DOI: 10.1007/s13300-019-0591-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
105 Pinho AR, Fortuna A, Falcão A, Santos AC, Seiça R, Estevens C, Veiga F, Ribeiro AJ. Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. J Pharm Anal 2019;9:143-55. [PMID: 31297291 DOI: 10.1016/j.jpha.2019.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
106 Gurova OY, Fadeev VV, Maloletkina ES. Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence. Diabetes mellitus 2019;21:524-533. [DOI: 10.14341/dm9603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obesity Reviews 2019;20:805-15. [DOI: 10.1111/obr.12839] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
108 Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Adv Ther 2019;36:265-77. [PMID: 30610613 DOI: 10.1007/s12325-018-0868-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
109 Cuomo A, Bolognesi S, Goracci A, Ciuoli C, Beccarini Crescenzi B, Maina G, Rosso G, Facchi E, Maccora C, Giordano N, Verdino V, Fagiolini A. Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity. Front Psychiatry 2018;9:784. [PMID: 30728788 DOI: 10.3389/fpsyt.2018.00784] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
110 Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab 2019;45:409-18. [PMID: 30615985 DOI: 10.1016/j.diabet.2018.12.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 16.3] [Reference Citation Analysis]
111 Sabiu S, Madende M, Ayokun-nun Ajao A, Adepemi Ogundeji O, Lekena N, Adekunle Alayande K. The scope of phytotherapy in southern African antidiabetic healthcare. Transactions of the Royal Society of South Africa 2019;74:1-18. [DOI: 10.1080/0035919x.2019.1575927] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
112 Hurley DL. Secondary Causes of Adipose Tissue Weight Gain. Bariatric Endocrinology 2019. [DOI: 10.1007/978-3-319-95655-8_10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Wang K, Liu D, Zhang Y, Chang X, Xu R, Pang J, Li K, Sun P, Zhu Y, Han X. SAD-A, a downstream mediator of GLP-1 signaling, promotes the phosphorylation of Bad S155 to regulate in vitro β-cell functions. Biochem Biophys Res Commun 2019;509:76-81. [PMID: 30573363 DOI: 10.1016/j.bbrc.2018.12.063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
114 Akturk HK, Rewers A, Joseph H, Schneider N, Garg SK. Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. Diabetes Technol Ther 2018;20:S224-32. [PMID: 29916737 DOI: 10.1089/dia.2018.0114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
115 Brandt SJ, Götz A, Tschöp MH, Müller TD. Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 2018;100:190-201. [PMID: 29412819 DOI: 10.1016/j.peptides.2017.12.021] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 15.4] [Reference Citation Analysis]
116 Miles KE, Kerr JL. Semaglutide for the Treatment of Type 2 Diabetes Mellitus. J Pharm Technol 2018;34:281-9. [PMID: 34861016 DOI: 10.1177/8755122518790925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
117 Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications 2019;33:236-42. [PMID: 30600136 DOI: 10.1016/j.jdiacomp.2018.11.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
118 Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Ther 2019;10:5-19. [PMID: 30506340 DOI: 10.1007/s13300-018-0535-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
119 Banskota S, Yousefpour P, Kirmani N, Li X, Chilkoti A. Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery. Biomaterials 2019;192:475-85. [PMID: 30504081 DOI: 10.1016/j.biomaterials.2018.11.012] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
120 Ku HC, Liang YJ. Incretin-based therapy for diabetic ulcers: from bench to bedside. Expert Opin Investig Drugs 2018;27:989-96. [PMID: 30449201 DOI: 10.1080/13543784.2018.1548607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
121 Sabet S, Condren ME, Boston AF, Doak LC, Chalmers LJ. Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus. J Pediatr Pharmacol Ther 2018;23:351-61. [PMID: 30429688 DOI: 10.5863/1551-6776-23.5.351] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Shimada I, Ueda T, Kofuku Y, Eddy MT, Wüthrich K. GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures. Nat Rev Drug Discov 2019;18:59-82. [PMID: 30410121 DOI: 10.1038/nrd.2018.180] [Cited by in Crossref: 131] [Cited by in F6Publishing: 134] [Article Influence: 26.2] [Reference Citation Analysis]
123 Takeuchi M, Okamoto M, Watanabe N. Pharmacological Evaluation of SKL-18287, a New Long-Acting Glucagon-Like Peptide-1 Receptor Agonist with Enhanced Aggregation Propensity, in Rodent Models. Int J Pept Res Ther 2019;25:1309-17. [DOI: 10.1007/s10989-018-9777-7] [Reference Citation Analysis]
124 Wang Q, Zhao C, Jin L, Zhang H, Miao Q, Liu H, Zhang D. AWRK6, a Novel GLP-1 Receptor Agonist, Attenuates Diabetes by Stimulating Insulin Secretion. Int J Mol Sci 2018;19:E3053. [PMID: 30301245 DOI: 10.3390/ijms19103053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Hinnen D. Overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes. J Am Assoc Nurse Pract 2018;30:S4-S11. [DOI: 10.1097/jxx.0000000000000115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Patel D. Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes. J Am Assoc Nurse Pract 2018;30:S29-42. [DOI: 10.1097/jxx.0000000000000112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
127 Kim KH, Lee IS, Park JY, Kim Y, An EJ, Jang HJ. Cucurbitacin B Induces Hypoglycemic Effect in Diabetic Mice by Regulation of AMP-Activated Protein Kinase Alpha and Glucagon-Like Peptide-1 via Bitter Taste Receptor Signaling. Front Pharmacol. 2018;9:1071. [PMID: 30298009 DOI: 10.3389/fphar.2018.01071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
128 Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, Taskinen MR, Borén J. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab 2019;21:84-94. [PMID: 30073766 DOI: 10.1111/dom.13487] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
129 Yuan X, Ni H, Chen X, Feng X, Wu Q, Chen J. Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora. J Cell Biochem 2018;119:10067-74. [PMID: 30129059 DOI: 10.1002/jcb.27343] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
130 Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018;391:2607-18. [PMID: 29945727 DOI: 10.1016/S0140-6736(18)30726-8] [Cited by in Crossref: 168] [Cited by in F6Publishing: 173] [Article Influence: 33.6] [Reference Citation Analysis]
131 Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication Safety Principles and Practice in CKD. Clin J Am Soc Nephrol 2018;13:1738-46. [PMID: 29915131 DOI: 10.2215/CJN.00580118] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
132 Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones 2018;17:333-50. [DOI: 10.1007/s42000-018-0038-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
133 Evers A, Bossart M, Pfeiffer-marek S, Elvert R, Schreuder H, Kurz M, Stengelin S, Lorenz M, Herling A, Konkar A, Lukasczyk U, Pfenninger A, Lorenz K, Haack T, Kadereit D, Wagner M. Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations. J Med Chem 2018;61:5580-93. [DOI: 10.1021/acs.jmedchem.8b00292] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
134 Demmel V, Sandberg-Schaal A, Jacobsen JB, Golor G, Pettersson J, Flint A. No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects. Diabetes Ther 2018;9:1441-56. [PMID: 29799100 DOI: 10.1007/s13300-018-0442-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
135 Poursharifi P, Madiraju SRM, Prentki M. Monoacylglycerol signalling and ABHD6 in health and disease. Diabetes Obes Metab. 2017;19 Suppl 1:76-89. [PMID: 28880480 DOI: 10.1111/dom.13008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
136 Menzel C, Holzeisen T, Laffleur F, Zaichik S, Abdulkarim M, Gumbleton M, Bernkop-schnürch A. In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide. Journal of Controlled Release 2018;277:165-72. [DOI: 10.1016/j.jconrel.2018.03.018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 15.0] [Reference Citation Analysis]
137 Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. Diabetes Ther 2018;9:1233-51. [PMID: 29713961 DOI: 10.1007/s13300-018-0428-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
138 Inman TR, Plyushko E, Austin NP, Johnson JL. The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes. Ther Adv Endocrinol Metab 2018;9:151-5. [PMID: 29796245 DOI: 10.1177/2042018818763698] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
139 Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs. Diabetes Ther 2018;9:1149-67. [PMID: 29675798 DOI: 10.1007/s13300-018-0424-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
140 Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res. 2018;2018:4020492. [PMID: 29805980 DOI: 10.1155/2018/4020492] [Cited by in Crossref: 37] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
141 Greydanus DE, Agana M, Kamboj MK, Shebrain S, Soares N, Eke R, Patel DR. Pediatric obesity: Current concepts. Disease-a-Month 2018;64:98-156. [DOI: 10.1016/j.disamonth.2017.12.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
142 Haluzík M, Adamíková A, Běhunčík M, Macko M, Štěpánová R. Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic. Vnitř Lék 2018;64:357-66. [DOI: 10.36290/vnl.2018.053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
143 Webb N, Orme M, Witkowski M, Nakanishi R, Langer J. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes. Diabetes Ther 2018;9:973-86. [PMID: 29574633 DOI: 10.1007/s13300-018-0397-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
144 Meece J. Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review. Diabetes Ther 2018;9:877-90. [PMID: 29574634 DOI: 10.1007/s13300-018-0395-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
145 Johnson EL, Frias JP, Trujillo JM. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgrad Med 2018;130:365-74. [PMID: 29569978 DOI: 10.1080/00325481.2018.1452515] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
146 Ahmed M. Management of Nonalcoholic Fatty Liver Disease (NAFLD). Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment 2018. [DOI: 10.5772/intechopen.72000] [Reference Citation Analysis]
147 Federici MO, McQuillan J, Biricolti G, Losi S, Lebrec J, Richards C, Miglio C, Norrbacka K. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. Diabetes Ther 2018;9:789-801. [PMID: 29525885 DOI: 10.1007/s13300-018-0396-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
148 Cheang JY, Moyle PM. Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes. ChemMedChem. 2018;13:662-671. [PMID: 29430842 DOI: 10.1002/cmdc.201700781] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
149 Nakashima K, Kaneto H, Shimoda M, Kimura T, Kaku K. Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism. Sci Rep 2018;8:3725. [PMID: 29487355 DOI: 10.1038/s41598-018-21751-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
150 Boniol M, Franchi M, Bota M, Leclercq A, Guillaume J, van Damme N, Corrao G, Autier P, Boyle P. Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies. Diabetes Care 2018;41:286-92. [PMID: 29146599 DOI: 10.2337/dc17-0280] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
151 Garczorz W, Gallego-Colon E, Kosowska A, Kłych-Ratuszny A, Woźniak M, Marcol W, Niesner KJ, Francuz T. Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation. Cardiovasc Ther 2018;36. [PMID: 29283509 DOI: 10.1111/1755-5922.12317] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
152 Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab 2018;20:998-1005. [PMID: 29205786 DOI: 10.1111/dom.13186] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
153 Anandhakrishnan A, Korbonits M. Glucagon-Like Peptide 1 and Human Obesity. Practical Guide to Obesity Medicine 2018. [DOI: 10.1016/b978-0-323-48559-3.00003-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
154 Mcglone ER, Ahmed AR. Metabolic Surgery, Reality or Myth: Scientific Side of Obesity Pathophysiology and Management. Global Bariatric Surgery 2018. [DOI: 10.1007/978-3-319-93545-4_36] [Reference Citation Analysis]
155 Kim GT, Sull JW, Jee SH. Effects of TLR4 Variants on Fasting Glucose Levels in a Korean Population. Korean J Clin Lab Sci 2017;49:345-349. [DOI: 10.15324/kjcls.2017.49.4.345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Newland DM, Edwards AR, Hall RC, Maxwell PR. Positive Impact of a Pilot Pharmacist-Run Diabetes Pharmacotherapy Clinic in Solid-Organ Transplant Recipients. Diabetes Spectr 2018;31:167-76. [PMID: 29773937 DOI: 10.2337/ds17-0029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
157 Niida A, Kanematsu-Yamaki Y, Asakawa T, Ishimura Y, Fujita H, Matsumiya K, Nishizawa N, Adachi Y, Mochida T, Tsuchimori K, Yoneyama-Hirozane M, Sakamoto J, Hirabayashi H, Fukui H, Takekawa S, Asami T. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives. Bioorg Med Chem 2018;26:566-72. [PMID: 29279243 DOI: 10.1016/j.bmc.2017.12.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
158 Suarez Castellanos I, Singh T, Balteanu B, Bhowmick DC, Jeremic A, Zderic V. Calcium-dependent ultrasound stimulation of secretory events from pancreatic beta cells. J Ther Ultrasound 2017;5:30. [PMID: 29214024 DOI: 10.1186/s40349-017-0108-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
159 Stryker MD, Kane MP, Busch RS. A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672). Endocrinol Diabetes Metab 2018;1:e00004. [PMID: 30815541 DOI: 10.1002/edm2.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
160 Hiyoshi T, Fujiwara M, Yao Z. Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes. J Biomed Res 2017. [PMID: 29089472 DOI: 10.7555/JBR.31.20160164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
161 Kosowska A, Gallego-Colon E, Garczorz W, Kłych-Ratuszny A, Aghdam MRF, Woz Niak M, Witek A, Wróblewska-Czech A, Cygal A, Wojnar J, Francuz T. Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells. Endocr Connect 2017;6:856-65. [PMID: 29042458 DOI: 10.1530/EC-17-0294] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
162 Unni S, Wittbrodt E, Ma J, Schauerhamer M, Hurd J, Ruiz-Negrón N, McAdam-Marx C. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab 2018;20:468-73. [PMID: 28862808 DOI: 10.1111/dom.13107] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
163 Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, Zacho J, Kaneko S. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab 2018;20:378-88. [PMID: 28786547 DOI: 10.1111/dom.13082] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
164 Gallego-Colon E, Klych-Ratuszny A, Kosowska A, Garczorz W, Aghdam MRF, Wozniak M, Francuz T. Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway. Pharmacol Rep 2018;70:178-83. [PMID: 29414148 DOI: 10.1016/j.pharep.2017.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
165 Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes 2017;10:403-12. [PMID: 29033597 DOI: 10.2147/DMSO.S141235] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 10.0] [Reference Citation Analysis]
166 Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology 2018;136:260-70. [PMID: 28927992 DOI: 10.1016/j.neuropharm.2017.09.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
167 Umpierrez GE, Bailey TS, Carcia D, Shaefer C, Shubrook JH, Skolnik N. Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies. J Diabetes 2018;10:94-111. [PMID: 28581207 DOI: 10.1111/1753-0407.12576] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
168 Johansen MY, MacDonald CS, Hansen KB, Karstoft K, Christensen R, Pedersen M, Hansen LS, Zacho M, Wedell-Neergaard AS, Nielsen ST, Iepsen UW, Langberg H, Vaag AA, Pedersen BK, Ried-Larsen M. Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA 2017;318:637-46. [PMID: 28810024 DOI: 10.1001/jama.2017.10169] [Cited by in Crossref: 109] [Cited by in F6Publishing: 111] [Article Influence: 18.2] [Reference Citation Analysis]
169 Gingras V, Taleb N, Roy-Fleming A, Legault L, Rabasa-Lhoret R. The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes. Diabetes Obes Metab 2018;20:245-56. [PMID: 28675686 DOI: 10.1111/dom.13052] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 9.8] [Reference Citation Analysis]
170 Skolnik N, Dupree RS, Johnson EL. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Current Medical Research and Opinion 2017;33:2187-94. [DOI: 10.1080/03007995.2017.1359518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
171 Pappachan JM, Viswanath AK. Medical Management of Diabesity: Do We Have Realistic Targets? Curr Diab Rep 2017;17:4. [PMID: 28101792 DOI: 10.1007/s11892-017-0828-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
172 Trujillo JM, Goldman J. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy 2017;37:927-43. [PMID: 28556176 DOI: 10.1002/phar.1962] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
173 Lioudaki E, Whyte M, Androulakis E, Stylianou K, Daphnis E, Ganotakis E. Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks. Clin Pharmacol Ther 2017;102:470-80. [DOI: 10.1002/cpt.731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
174 Okiro JO, Mc Hugh C, Abdalla A. Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists? BMJ Case Reports 2017. [DOI: 10.1136/bcr-2017-220437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
175 Hunt B, McConnachie CC, Gamble C, Dang-Tan T. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. J Med Econ 2017;20:1117-20. [PMID: 28651479 DOI: 10.1080/13696998.2017.1347793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
176 Schaid MD, Wisinski JA, Kimple ME. The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease. AAPS J 2017;19:1276-83. [PMID: 28584908 DOI: 10.1208/s12248-017-0097-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
177 Ji Q. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. Clin Ther. 2017;39:1244-1264. [PMID: 28526416 DOI: 10.1016/j.clinthera.2017.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
178 Zheng J, Zheng S, Feng Q, Zhang Q, Xiao X. Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications. Biosci Rep 2017;37:BSR20170286. [PMID: 28424369 DOI: 10.1042/BSR20170286] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 12.8] [Reference Citation Analysis]
179 Potenza MA, Nacci C, De Salvia MA, Sgarra L, Collino M, Montagnani M. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacol Res 2017;120:226-41. [PMID: 28408314 DOI: 10.1016/j.phrs.2017.04.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
180 Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab 2017;22:15-26. [PMID: 28443255 DOI: 10.6065/apem.2017.22.1.15] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
181 Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes Obes Metab 2017;19:842-9. [PMID: 28124820 DOI: 10.1111/dom.12890] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
182 Mezquita-Raya P, Ramírez de Arellano A, Kragh N, Vega-Hernandez G, Pöhlmann J, Valentine WJ, Hunt B. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Ther 2017;8:401-15. [PMID: 28224463 DOI: 10.1007/s13300-017-0239-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
183 Wright JJ, Tylee TS. Pharmacologic Therapy of Type 2 Diabetes. Med Clin North Am 2016;100:647-63. [PMID: 27235609 DOI: 10.1016/j.mcna.2016.03.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
184 Hunt B, Ye Q, Valentine WJ, Ashley D. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom. Diabetes Ther 2017;8:129-47. [PMID: 28058656 DOI: 10.1007/s13300-016-0219-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
185 Leroy JM, Stellpflug SJ. Antidiabetic Agents. Critical Care Toxicology 2017. [DOI: 10.1007/978-3-319-17900-1_112] [Reference Citation Analysis]
186 Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 [PMID: 28031776 DOI: 10.4239/wjd.v7.i20.572] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
187 Bodnaruc AM, Prud'homme D, Blanchet R, Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab (Lond) 2016;13:92. [PMID: 27990172 DOI: 10.1186/s12986-016-0153-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
188 Lakkireddy HR, Urmann M, Besenius M, Werner U, Haack T, Brun P, Alié J, Illel B, Hortala L, Vogel R, Bazile D. Oral delivery of diabetes peptides - Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv Drug Deliv Rev 2016;106:196-222. [PMID: 26964477 DOI: 10.1016/j.addr.2016.02.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
189 Aschenbrenner DS. New Injectable Drug for Type 2 Diabetes. Am J Nurs 2016;116:22-3. [PMID: 27787319 DOI: 10.1097/01.NAJ.0000505586.55332.9d] [Reference Citation Analysis]
190 Shu H, Gu LN, Men LC, Lu JM. Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis. Diabetes Ther 2016;7:777-92. [PMID: 27796905 DOI: 10.1007/s13300-016-0207-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
191 Isaacs D, Prasad-reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. American Journal of Health-System Pharmacy 2016;73:1493-507. [DOI: 10.2146/ajhp150990] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
192 Lee EJ, Kim TN. Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. KJO 2016;25:121-8. [DOI: 10.7570/kjo.2016.25.3.121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
193 Roca-Rodríguez MM, Muros de Fuentes MT, Piédrola-Maroto G, Quesada-Charneco M, Maraver-Selfa S, Tinahones FJ, Mancha-Doblas I. [Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control]. Aten Primaria 2017;49:294-9. [PMID: 27667144 DOI: 10.1016/j.aprim.2016.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
194 Martel J, Ojcius DM, Chang C, Lin C, Lu C, Ko Y, Tseng S, Lai H, Young JD. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat Rev Endocrinol 2017;13:149-60. [DOI: 10.1038/nrendo.2016.142] [Cited by in Crossref: 161] [Cited by in F6Publishing: 167] [Article Influence: 23.0] [Reference Citation Analysis]
195 Jain N, Savani M, Agarwal M, Sands CW. Albiglutide-induced pancreatitis. Ther Adv Drug Saf 2016;7:236-8. [PMID: 27904741 DOI: 10.1177/2042098616667352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
196 Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs 2016;25:1167-79. [PMID: 27563838 DOI: 10.1080/13543784.2016.1221925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
197 Bae EJ. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Arch Pharm Res 2016;39:1114-28. [PMID: 27502601 DOI: 10.1007/s12272-016-0813-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
198 Qiao Q, Johnsson K, Grandy S, Kostev K. Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany. J Diabetes Sci Technol 2017;11:272-7. [PMID: 27470665 DOI: 10.1177/1932296816661349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
199 Ionut V, Woolcott OO, Mkrtchyan HJ, Stefanovski D, Kabir M, Iyer MS, Liu H, Castro AV, Wu Q, Broussard JL, Kolka CM, Asare-Bediako I, Bergman RN. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes. PLoS One 2016;11:e0158703. [PMID: 27398720 DOI: 10.1371/journal.pone.0158703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
200 Meetoo D, Wong L, Alsomali S. Pharmacological options for managing type 2 diabetes. Nurse Prescribing 2016;14:330-338. [DOI: 10.12968/npre.2016.14.7.330] [Reference Citation Analysis]
201 Jazayeri A, Andrews SP, Marshall FH. Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists. Chem Rev 2017;117:21-37. [PMID: 27333206 DOI: 10.1021/acs.chemrev.6b00119] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
202 Nomiyama T, Yanase T. GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control. Expert Rev Endocrinol Metab 2016;11:357-64. [PMID: 30058925 DOI: 10.1080/17446651.2016.1191349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Amouyal C, Andreelli F. Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? J Diabetes Res 2016;2016:5908656. [PMID: 27382574 DOI: 10.1155/2016/5908656] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
204 Lee SJ, Diener K, Kaufman S, Krieger JP, Pettersen KG, Jejelava N, Arnold M, Watts AG, Langhans W. Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4. Mol Metab 2016;5:552-65. [PMID: 27408779 DOI: 10.1016/j.molmet.2016.04.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
205 Schernthaner-Reiter MH, Schernthaner G. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. Expert Rev Endocrinol Metab 2016;11:281-96. [PMID: 30058933 DOI: 10.1586/17446651.2016.1151783] [Reference Citation Analysis]
206 Chon S, Gautier JF. An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass. Diabetes Metab J 2016;40:99-114. [PMID: 27126881 DOI: 10.4093/dmj.2016.40.2.99] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
207 Guo NJ, Li J, Zhu YF, Guo LR, Chen QF, Huang B. Exenatide inhibits fatty acid induced hepatocyte steatosis and inflammation through activating AMPK. Shijie Huaren Xiaohua Zazhi 2016; 24(11): 1649-1657 [DOI: 10.11569/wcjd.v24.i11.1649] [Reference Citation Analysis]
208 Rodríguez-Cabello JC, Arias FJ, Rodrigo MA, Girotti A. Elastin-like polypeptides in drug delivery. Adv Drug Deliv Rev 2016;97:85-100. [PMID: 26705126 DOI: 10.1016/j.addr.2015.12.007] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 13.6] [Reference Citation Analysis]
209 Baldassano S, Amato A, Caldara GF, Mulè F. Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet. Endocrine 2016;54:648-56. [PMID: 26832341 DOI: 10.1007/s12020-016-0871-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
210 Verma A, Verma D. TREATMENT OF OBESITY: NEWER PERSPECTIVES. jemds 2016;5:112-113. [DOI: 10.14260/jemds/2016/27] [Reference Citation Analysis]
211 Leroy JM, Stellpflug SJ. Antidiabetic Agents. Critical Care Toxicology 2016. [DOI: 10.1007/978-3-319-20790-2_112-1] [Reference Citation Analysis]
212 Tomlinson B, Hu M, Zhang Y, Chan P, Liu Z. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 2016;25:145-58. [DOI: 10.1517/13543784.2016.1123249] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]